The precise mechanism by which DARPP-32 exerts its influence on breast cancer remains poorly understood, nevertheless, current evidence suggests that DARPP-32 may act as a key regulator and/or activator of several critical signalling pathways implicated in cancer development and progression. This evidence concerns the gene PPP1R1B and breast carcinoma.